Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.

J Diabetes Investig · 2018 · PMC6031500 · PMID 28984041

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

With the exception of patients pretreated with α‐glucosidase inhibitors, the reduction in HbA1c observed with liraglutide compared with additional OAD did not reach statistical significance in other pretrial OAD groups (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.